Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine

  • Y. C
  • O. W
  • M.B.H. Y
 et al. 
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Antipsychotic treatment combined with Selective Serotonin Reuptake Inhibitor (SSRI) antidepressant can improve negative symptoms in schizophrenic patients that are unresponsive to antipsychotic drugs alone. The mechanism of this therapeutic effect is not clear. The current study examined molecular changes induced by the combined treatment in human peripheral mononuclear cells (PMC) in order to get insight into its mechanism of action. Gene expression profile of PMC from antipsychotic-treated patients was examined before addition of the SSRI fluvoxamine, and 3 and 6 weeks after. Gene expression patterns screened with a cDNA array, comprising 1176 genes, revealed homologous changes in a range of transcripts related to G-protein coupled receptors (GPCR). Genes related to GPCR-family were assayed using customized cDNA array and the results verified by real-time RT-PCR. The mRNA expression of chemokine receptors, IL8RA and CCR1, and of RGS7 was significantly down-regulated following fluvoxamine augmentation. The clinical assessments showed improvement in negative symptoms following the combined treatment. The transcriptional analysis suggests that the therapeutic mechanism of the combined antipsychotic-fluvoxamine treatment may involve genes associated with G-protein coupled receptors (GPCR). Our findings suggest that gene expression changes in PMC may be useful in investigating the mechanism of drug action in schizophrenia. © 2007 Elsevier Inc. All rights reserved.

Author-supplied keywords

  • *fluvoxamine/cb [Drug Combination]
  • *fluvoxamine/dt [Drug Therapy]
  • *neuroleptic agent/cb [Drug Combination]
  • *schizophrenia/dt [Drug Therapy]
  • Antipsychotic
  • Chemokine receptors
  • DNA microarray
  • G protein coupled receptor
  • G-proteins
  • SSRI
  • Schizophrenia
  • adult
  • article
  • chemokine receptor
  • chemokine receptor CCR1
  • clinical assessment
  • clinical trial
  • complementary DNA
  • down regulation
  • drug mechanism
  • gene expression
  • genetic screening
  • genetic transcription
  • human
  • male
  • messenger RNA
  • negative syndrome
  • nucleotide sequence
  • olanzapine/cb [Drug Combination]
  • olanzapine/dt [Drug Therapy]
  • olanzapine/po [Oral Drug Administration]
  • peripheral blood mononuclear cell
  • real time polymerase chain reaction
  • risperidone/cb [Drug Combination]
  • risperidone/dt [Drug Therapy]
  • risperidone/po [Oral Drug Administration]
  • serotonin uptake inhibitor
  • zuclopenthixol decanoate/cb [Drug Combination]
  • zuclopenthixol decanoate/dt [Drug Therapy]
  • zuclopenthixol decanoate/im [Intramuscular Drug Ad
  • zuclopenthixol/cb [Drug Combination]
  • zuclopenthixol/dt [Drug Therapy]
  • zuclopenthixol/im [Intramuscular Drug Administrati

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in


  • Chertkow Y.

  • Weinreb O.

  • Youdim M.B.H.

  • Silver H.

  • Y Chertkow

  • O Weinreb

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free